Quote this publication Share Print

OZURDEX

-
Opinions on drugs - Posted on Mar 19 2013

Reason for request

Request for inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use in the extension of indication to the “treatment of adults with inflammation of the posterior segment of the eye presenting as non-infectious uveitis”.

-


Clinical Benefit

Substantial

The actual benefit of OZURDEX 700 micrograms, intravitreal implant in applicator, is substantial in this indication.


Clinical Added Value

moderate

OZURDEX 700 μg, intravitreal implant in applicator, provides a moderate improvement in actual benefit (IAB III) in the management of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis.


Contact Us

Évaluation des médicaments

See also